BioVaxys Technology(DE:5LB0)
€0.030.00 (0.00%)
DE:5LB0
BioVaxys Technology financials statements
€0.03
At close:0.00 (0.00%)
BioVaxys Technology (5LB0) Ratios
0 Followers
BioVaxys Technology Ratios
DE:5LB0's free cash flow for Q3 2025 was C$-1.06M. For the 2025 fiscal year, DE:5LB0's free cash flow was increased by C$0.00 and operating cash flow was C$-1.06M. See a summary of the company’s cash flow.
| Ratios | Oct 24 | Apr 24 | Jan 23 | Jan 22 | Jan 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.40 | 0.03 | 0.44 | 2.68 | 3.40 |
| Quick Ratio | 0.40 | 0.06 | 0.44 | 2.68 | 3.40 |
| Cash Ratio | 0.07 | 0.00 | 0.09 | 1.81 | 2.69 |
| Solvency Ratio | -1.23 | -1.52 | -4.83 | -19.64 | -1.30 |
| Operating Cash Flow Ratio | -0.58 | -0.30 | -0.96 | -16.20 | -1.36 |
| Short-Term Operating Cash Flow Coverage | -27.35 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | C$ -1.92M | C$ -3.37M | C$ -924.57K | C$ 547.62K | C$ 2.16M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | -0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | -0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.68 | -0.03 | -1.12 | 1.04 | 1.09 |
| Debt Service Coverage Ratio | -58.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | -258.82 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.04 | 0.00 | 0.00 | 0.09 | 2.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 106.50% |
| EBT Per EBIT | 120.00% | 319.96% | 287.31% | 100.25% | 100.39% |
| Return on Assets (ROA) | -304.04% | -6774.28% | -1354.89% | -75.94% | -11.23% |
| Return on Equity (ROE) | 205.97% | 227.97% | 1516.09% | -78.98% | -12.29% |
| Return on Capital Employed (ROCE) | 171.63% | 71.25% | 527.68% | -78.79% | -11.49% |
| Return on Invested Capital (ROIC) | 177.94% | 71.25% | 527.68% | -78.79% | -11.49% |
| Return on Tangible Assets | -304.04% | -6774.28% | -1354.89% | -583.50% | -38.35% |
| Earnings Yield | -28.87% | -229.22% | -58.27% | -21.05% | -9.31% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.10 | -0.08 | -0.16 | -0.64 | -0.41 |
| Free Cash Flow Per Share | -0.15 | -0.08 | -0.16 | -0.64 | -0.41 |
| Dividend Paid and CapEx Coverage Ratio | -1.76 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -1.76 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -27.35 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -21.30% | -31.45% | -7.82% | -17.25% | -9.72% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.46 | -0.44 | -1.72 | -4.75 | -10.75 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -7.14 | -0.99 | -26.02 | 3.75 | 1.32 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.69 | -3.18 | -12.78 | -5.80 | -10.29 |
| Price-to-Operating Cash Flow Ratio | -7.36 | -3.18 | -12.78 | -5.80 | -10.29 |
| Price-to-Earnings Growth (PEG) Ratio | 0.05 | 0.01 | -0.03 | -0.06 | -0.04 |
| Enterprise Value Multiple | -3.43 | -0.44 | 0.00 | -4.69 | -9.32 |
| Enterprise Value | 13.56M | 3.35M | 19.98M | 30.09M | 10.20M |
| EV to EBITDA | -3.43 | -0.44 | 0.00 | -4.69 | -9.32 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -4.64 | -3.18 | -12.69 | -5.68 | -8.31 |
| EV to Operating Cash Flow | -7.28 | -3.18 | -12.69 | -5.68 | -8.31 |
| Tangible Book Value Per Share | -0.10 | -0.25 | -0.08 | 0.09 | 0.72 |
| Shareholders’ Equity Per Share | -0.10 | -0.25 | -0.08 | 0.99 | 3.18 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.20 | -0.57 | -1.19 | -0.78 | -0.39 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.07 |
| Interest Burden | 1.00 | 1.00 | 3.08 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.47 | 0.14 | 0.13 | 0.82 | 1.11 |
Currency in CAD
